Evidence map›Paper›PMID 34898573›Full record

ArticleCurrent oncology (Toronto, Ont.)2021

Association of Melanoma-Risk Variants with Primary Melanoma Tumor Prognostic Characteristics and Melanoma-Specific Survival in the GEM Study.

Danielle R Davari, Irene Orlow, Peter A Kanetsky, Li Luo, Klaus J Busam, Ajay Sharma, Anne Kricker, Anne E Cust, Hoda Anton-Culver, Stephen B Gruber and 10 more

Open access · goldAbstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. GermlineBiomolecules · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 11 institutions in 5 countries.

Danielle R DavariDepartment of Dermatology, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0001-6738-9418
Irene OrlowDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-6234-6961
Peter A KanetskyDepartment of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.ORCID 0000-0002-5567-9618
Li LuoDepartment of Internal Medicine, University of New Mexico Cancer Center, University of New Mexico, Albuquerque, NM 87102, USA.ORCID 0000-0003-0728-8628
Klaus J BusamDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Ajay SharmaDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Anne KrickerSydney School of Public Health, The University of Sydney, Sydney, NSW 2006, Australia.ORCID 0000-0002-7219-1227
Anne E CustDaffodil Centre, The University of Sydney, a Joint Venture with Cancer Council NSW, Sydney, NSW 2006, Australia.ORCID 0000-0002-5331-6370
Hoda Anton-CulverDepartment of Medicine, University of California, Irvine, CA 92697, USA.
Stephen B GruberCity of Hope National Medical Center, Duarte, CA 91010, USA.
Richard P GallagherBC Cancer and Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC V5Z 1L3, Canada.
Roberto ZanettiPiedmont Cancer Registry, Centre for Epidemiology and Prevention in Oncology in Piedmont, 10156 Turin, Italy.ORCID 0000-0001-6498-4086
Stefano RossoPiedmont Cancer Registry, Centre for Epidemiology and Prevention in Oncology in Piedmont, 10156 Turin, Italy.ORCID 0000-0001-6816-2661
Lidia SacchettoPiedmont Cancer Registry, Centre for Epidemiology and Prevention in Oncology in Piedmont, 10156 Turin, Italy.
Terence DwyerMurdoch Children's Research Institute, Melbourne, VIC 3052, Australia.ORCID 0000-0002-2091-7663
David C GibbsSchool of Medicine, Emory University, Atlanta, GA 30322, USA.
David W OllilaDepartment of Surgery, University of North Carolina, Chapel Hill, NC 27599, USA.
Colin B BeggDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Marianne BerwickDepartment of Internal Medicine, University of New Mexico Cancer Center, University of New Mexico, Albuquerque, NM 87102, USA.
Nancy E ThomasDepartment of Dermatology, University of North Carolina, Chapel Hill, NC 27599, USA.
Memorial Sloan Kettering Cancer Center · USPiedmont Reference Center for Epidemiology and Cancer Prevention · ITUniversity of North Carolina at Chapel Hill · USThe University of Sydney · AUUniversity of New Mexico · USCity Of Hope National Medical Center · USEmory University · USMoffitt Cancer Center · USThe University of Melbourne · AUUniversity of British Columbia · CAUniversity of California, Irvine · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008169 · NIGMS · EMORY UNIVERSITY · PI GROSS, ROBERT E · 1987 to 2021
$20.3M
Sex Differences in Methylome Alterations and Mutational Burden in Early Stage MelanomaP01CA206980 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI BERWICK, MARIANNE, THOMAS, NANCY E. · 2017 to 2022
$10.1M
Melanoma RAS/BRAF Mutation:Heterogeneity-Risk-PrognosisR01CA112243 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI THOMAS, NANCY E. · 2005 to 2014
$5.4M
A MODEL FOR GENETIC SUSCEPTIBILITY: MELANOMAU01CA083180 · NCI · UNIVERSITY OF NEW MEXICO · PI BERWICK, MARIANNE · 1999 to 2003
$5.2M
Identification of Lethal Melanomas at the Time of DiagnosisR01CA233524 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ANTON-CULVER, HODA A, BEGG, COLIN B · 2020 to 2024
$4.5M
Solar Exposure and Melanoma SurvivalR01CA112524 · NCI · UNIVERSITY OF NEW MEXICO · PI BERWICK, MARIANNE · 2005 to 2009
$2.5M
Epidemiologic Parameters of Rare Cancer Risk FactorsR01CA098438 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI BEGG, COLIN B · 2003 to 2005
$839k
Validation of the use of whole-genome amplified DNA in a population-based studyR03CA173806 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ORLOW, IRENE · 2013 to 2014
$170k
Mutational Analysis of Clonality in Multiple Primary MelanomaR03CA125829 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ORLOW, IRENE · 2006 to 2007
$128k
NCI NIH HHS P01 CA206980NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA098438NCI NIH HHS R01 CA112243NCI NIH HHS R01 CA112524NCI NIH HHS R01 CA233524NCI NIH HHS R03 CA125829NCI NIH HHS R03 CA173806NCI NIH HHS U01 CA083180NIGMS NIH HHS T32 GM008169
6 · The paper itself

Abstract

Genome-wide association studies (GWAS) and candidate pathway studies have identified low-penetrant genetic variants associated with cutaneous melanoma. We investigated the association of melanoma-risk variants with primary melanoma tumor prognostic characteristics and melanoma-specific survival. The Genes, Environment, and Melanoma Study enrolled 3285 European origin participants with incident invasive primary melanoma. For each of 47 melanoma-risk single nucleotide polymorphisms (SNPs), we used linear and logistic regression modeling to estimate, respectively, the per allele mean changes in log of Breslow thickness and odds ratios for presence of ulceration, mitoses, and tumor-infiltrating lymphocytes (TILs). We also used Cox proportional hazards regression modeling to estimate the per allele hazard ratios for melanoma-specific survival. Passing the false discovery threshold (

Indexed as

MelanomaSkin NeoplasmsGenome-Wide Association StudyHumansLymphocytes, Tumor-InfiltratingPrognosisBreslow thicknessmelanomamitosessingle nucleotide polymorphismsurvivaltumor-infiltrating lymphocytesulceration

Identifiers

PMID34898573
PMCPMC8628692
OpenAlexW3212411205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.